An official website of the United States government

Search
Filters

Study Acronym

HALT PKD

1 - 34 of 34 Results
  • Previous
  • 1(current)
  • Next
Page
Show:
Study Search Results Table
Title
PMID
PMCID
Public Release Type
Publication Year
DOI
Study Acronym
Request ID(s)
Public Release Origin
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure37330614Journal202310.1038/s41591-023-02418-0HALT PKD, FONT II, FSGS/FONT22864, 23584Secondary Research
ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing29203126PMC6267804Journal201810.1053/j.ajkd.2017.09.008HALT PKD20790Secondary Research
Acute treatment effects on GFR in randomized clinical trials of kidney disease progression.34862238PMC8819983Journal202210.1681/ASN.2021070948HALT PKD21181Secondary Research
Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease29290310PMC5826779Journal201710.1016/j.kint.2017.09.027HALT PKD20790Secondary Research
CD8+ T cells modulate autosomal dominant polycystic kidney disease progression30249452PMC6319903Journal201810.1016/j.kint.2018.06.025HALT PKD20959Secondary Research
Change in albuminuria and GFR slope as joint surrogate endpoints for kidney failure - Implications for phase 2 clinical trials in chronic kidney disease36918388Journal202310.1681/ASN.0000000000000117HALT PKD21181Secondary Research
Collagen IV Gene Mutations in Adults With Bilateral Renal Cysts and CKD31922066PMC6943786Journal201910.1016/j.ekir.2019.09.004HALT PKD21532, 21588, 21748Secondary Research
Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease.31874800PMC7218796Journal202010.1016/j.kint.2019.08.038HALT PKD20790, 20959, 21225, 21507, 22080Secondary Research
Development of a Clinical Trial Enrichment (CTE) Tool for Autosomal Dominant Polycystic Kidney DiseaseConference Presentation2023HALT PKD, CRISP22905Secondary Research
Effects of Tolvaptan on Kidney Function Decline in Patients Aged >55 Years With Autosomal Dominant Polycystic Kidney Disease: Pooled Data Analysis37250503PMC10220412Journal202310.1016/j.xkme.2023.100639HALT PKD, CRISP21540Secondary Research
Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD)29401581PMC5901382Journal201810.1096/fj.201700909RHALT PKD21532, 21588Secondary Research
Impact of early glomerular filtration rate decline in response to antihypertensive treatment on risk of end-stage kidney disease and cardiovascular outcomes: a systematic review and meta-analysis34930868Journal202210.1097/HJH.0000000000003066HALT PKD23180Secondary Research
Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease.33305291PMC7725226Journal202010.34067/KID.0001692020HALT PKD20790, 20959Secondary Research
KIDNEY FUNCTION DECLINE IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE PATIENTS: ASSESSMENT OF TOLVAPTAN'S REAL WORLD EFFECTIVENESSConference Presentation2023HALT PKD, CRISP21540Secondary Research
KIM-1 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease: HALT-PKD Results.32541154PMC7384479Journal202010.1159/000508051HALT PKD20959, 22080Secondary Research
Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.30922668PMC6478515Journal201910.1016/j.kint.2018.12.023HALT PKD20790Secondary Research
Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease.29854969PMC5976807Journal201810.1016/j.ekir.2017.12.011HALT PKD20790Secondary Research
Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype.34890546PMC8764120Journal202210.1016/j.ajhg.2021.11.016HALT PKD21225Secondary Research
Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.27259053PMC4908191Journal201610.1016/j.ajhg.2016.05.004HALT PKD20790, 21225Secondary Research
Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.29118087PMC5791072Journal201810.1681/ASN.2017070819HALT PKD20790, 20959Secondary Research
Overweight and Obesity and Progression of ADPKD34117082PMC8216617Journal202110.2215/CJN.16871020HALT PKD20959, 22080Secondary Research
POOLED DATA ANALYSIS OF THE EFFECT OF TOLVAPTAN IN PATIENTS AGED 18-35 YEARS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE35570988PMC9091612Conference Presentation202310.1016/j.ekir.2022.02.009HALT PKD, CRISP21540Secondary Research
Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Studies.34401721PMC8350824Journal202110.1016/j.xkme.2021.03.004HALT PKD20790, 20959, 22080Secondary Research
Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.30803434PMC6388487Journal201910.1186/s12882-019-1249-6HALT PKD20790, 21328Secondary Research
Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.26823553PMC5004648Journal201610.1681/ASN.2015050583HALT PKD20790Secondary Research
The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD.36204243PMC9529969Journal202210.1016/j.xkme.2022.100538HALT PKD20790, 20997Secondary Research
The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations.29395486PMC6057824Journal201810.1053/j.ajkd.2017.11.015HALT PKD21225, 21507Secondary Research
The tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression36422996PMC9870090Journal202310.1172/jci.insight.154773HALT PKD20959, 22080Secondary Research
The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD.32634120PMC7455088Journal202010.1172/jci.insight.138724HALT PKD20790Secondary Research
Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies.37250503PMC10220412Journal202310.1016/j.xkme.2023.100639HALT PKD21540Secondary Research
Vascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney Disease30228110PMC6218833Journal201810.2215/CJN.05850518HALT PKD20959Secondary Research
Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease.35217526PMC8975034Journal202210.2215/CJN.08660621HALT PKD20790Secondary Research
Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease35059607PMC8760407Journal202110.1016/j.isci.2021.103697HALT PKD20959, 22080Secondary Research
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International35134221PMC9035348Journal202210.1093/ndt/gfab312HALT PKD21225Secondary Research
  • Previous
  • 1(current)
  • Next
Page